WTA
HRTX icon

Washington Trust Advisors’s Heron Therapeutics HRTX Stock Holding History

Washington Trust Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-367
Closed -$1.28K – 675
2024
Q2 		$1.28K Hold
367
– – ﹤0.01% 642
2024
Q1 		$1.02K Hold
367
– – ﹤0.01% 652
2023
Q4 		$624 Hold
367
– – ﹤0.01% 661
2023
Q3 		$379 Hold
367
– – ﹤0.01% 668
2023
Q2 		$426 Hold
367
– – ﹤0.01% 652
2023
Q1 		$555 Hold
367
– – ﹤0.01% 768
2022
Q4 		$918 Hold
367
– – ﹤0.01% 767
2022
Q3 		$2K Hold
367
– – ﹤0.01% 854
2022
Q2 		$1K Hold
367
– – ﹤0.01% 910
2022
Q1 		$2K Hold
367
– – ﹤0.01% 947
2021
Q4 		$3K Buy
+367
New +$3.75K ﹤0.01% 919

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Washington Trust Advisors's HRTX Position: Q3 2024 in Review

Washington Trust Advisors sold out of Heron Therapeutics (HRTX) in Q3 2024, closing a stake of 367 shares — an estimated $1.28K sold.

Washington Trust Advisors first reported a position in HRTX in Q4 2021 and held it in 11 quarters. The position peaked at $3K in Q4 2021. 173 funds tracked by Wall St. Rank hold HRTX as of Q3 2024.

  • Washington Trust Advisors reported no remaining Heron Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Washington Trust Advisors sold 367 Heron Therapeutics shares in Q3 2024, an estimated $1.28K.
  • Washington Trust Advisors first reported a position in Heron Therapeutics in Q4 2021 and held it in 11 quarters.
  • Washington Trust Advisors's Heron Therapeutics position peaked at $3K in Q4 2021.
  • 173 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2024.

Based on Washington Trust Advisors's 13F filing for Q3 2024, filed 1 Nov 2024.